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liver and embracing complexity
A lovely study in this month’s issue of the Journal provides a nice
example of using complementary approaches to dissect cell-
speciﬁc function in an animal model of liver injury. The study
by Morán-Salvador et al. examines the contributions of PPARc
activity in both parenchymal and non-parenchymal cells during
CCl4-induced liver injury by combining a method to genetically
deplete this gene in speciﬁc cell types in vivo with a model of
tissue function using precision cut liver slices (PCLS) ex vivo.
PPARc (peroxisome proliferator activated receptor gamma) is
a well characterized nuclear transcription factor that is one of
three subtypes of this receptor family, which also includes PPARs
a and b/d [1]. The receptors always pair with the Retinoid X
receptor (RXR) to form obligate heterodimers in regulating gene
expression, and, like other nuclear receptors, they engage speciﬁc
ligands in the cytoplasm, then translocate to the nucleus where
they regulate gene targets by binding to discrete DNA promoter
elements. PPARc has two isoforms generated through alternative
splicing, PPARc1 and PPARc2, each with a distinct tissue distribu-
tion and repertoire of target genes; in the Morán-Salvador study,
changes in their model were largely restricted to PPARc1.
Although only a few endogenous ligands for PPARc have been
identiﬁed, the discovery of thiazolidinedinones (TZDs) as syn-
thetic PPARc activators that sensitize insulin signaling has led
to their widespread use as antidiabetic agents. More recently,
however, enthusiasm for using them has waned because of con-
cerns about increased adverse cardiac events, as well as edema
and weight gain associated with these agents (e.g., rosiglitazone
or Avandia, and pioglitazone or Actos) [2]. The concerns not-
withstanding, the discovery of these ﬁrst generation synthetic
PPARc ligands has been instrumental in clarifying PPARc’s mech-
anisms of action in regulating lipid homeostasis, inﬂammatory
signaling and glucose regulation.
Given PPARc’s very broad range of potential activities and
off-target effects, it has been essential to deﬁne both its tissue-Journal of Hepatology 20
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Open access under CC BY-NC-ND license.speciﬁc and cell-speciﬁc effects. The molecule contributes signif-
icantly, but sometimes divergently to a range of pathways in
adipose, skeletal muscle, immune cells, bone and brain, among
others [1]. In liver, clarifying the cell-speciﬁc effects is especially
pertinent given the important contributions of dyslipidemia,
inﬂammation and insulin resistance to the rising prevalence of
non-alcoholic steatohepatitis (NASH). Yet, to date, the effects
attributed to PPARc in liver are uncertain and sometimes contra-
dictory. The authors of the current manuscript and others have
previously suggested that PPARc agonism promotes steatosis
through enhanced lipid uptake by hepatocytes [3–5], whereas
at least one study has demonstrated the opposite effect [6]. In
stellate cells, the key ﬁbrogenic cell in liver, studies have consis-
tently reported that increased PPARc signaling attenuates cellular
activation and is antiﬁbrotic [7–9]. In inﬂammatory cells includ-
ing macrophages, dendritic cells and lymphocytes, different sub-
sets each respond uniquely to PPARc signaling [1].
How does one tease out the speciﬁc cellular responses to a
broadly expressed signaling pathway in a complex tissue? The
development of cell-speciﬁc knockout technology in experimental
mouse models offers an ingenious solution. In this widely exploited
technique, a mouse is generated in which a gene locus of interest, in
this case PPARc, is genetically altered so that the locus is ﬂanked in
every cell type by a target sequence known as LoxP, which is recog-
nized speciﬁcally by an exogenous bacteriophage enzyme known as
Cre recombinase. If constructed properly, these mice with ‘ﬂoxed
alleles’ (i.e., ﬂanked by LoxP) have normal gene function. However,
when Cre is expressed in speciﬁc tissues, Cre-Lox-mediated recom-
bination occurs, effectively replacing the functioning gene with one
that is inactivated. To achieve cell-speciﬁc gene knockout, mice
with these ﬂoxed alleles can be mated with another mouse line
in which Cre expression only occurs in those cells where the pro-
moter that drives Cre is active [10].
This is exactly the strategy used by Morán-Salvador and col-
leagues to dissect the relative contributions of PPARc expressed
by hepatocytes, macrophages, and stellate cells to CCl4 liver
injury. They crossed the same PPARc ﬂoxed mouse line with
three different Cre-expressing mouse lines, one expressing albu-
min-Cre (Alb-Cre) for hepatocytes, lysozyme M-Cre (LysM-Cre)
for inﬂammatory cells, and adipocyte fatty acid-binding pro-
tein-Cre (aP2-Cre) for hepatic stellate cells. Their results clearly
indicate that deletion of PPARc in inﬂammatory cells, and to a
lesser extent in hepatocytes, signiﬁcantly worsened CCl4 liver13 vol. 59 j 915–917
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injury, lipid peroxidation and death of hepatocytes. Increased
injury was associated both with signiﬁcant elevations in isolated
macrophages of several inﬂammatory mediators, including COX-
2, TNFa, CXCL2 and IL-1b, and with increased ﬁbrosis in vivo.
Similarly, deletion of PPARc in stellate cells by expression of
aP2-Cre led to ampliﬁed CCl4 liver injury and ﬁbrosis. These data
support the conclusion that PPARc normally suppresses inﬂam-
mation and injury, whereas its deletion ampliﬁes these features.
While these in vivo ﬁndings evince the power of cell-speciﬁc
gene deletion to clarify disease pathogenesis, they do not exclude
the possible contribution from cells expressing Cre outside the
liver, since both LysM-Cre and aP2-Cre gene expression is not
restricted to the liver, with LysM expressed in all macrophages
and neutrophils, and aP2-Cre also expressed in adipocytes. This
is an important concern in view of the prevailing evidence that
cross talk between liver and other organs (especially adipose)
mediates some features of NASH [11]. In other words, did circu-
lating cells derived from adipose or elsewhere account for the
enhanced inﬂammation in liver following PPARc deletion?
To exclude the impact of circulating factors from other organs
on the liver phenotype, the authors used precision cut liver slices
(PCLS), a well established technique that has the advantage of pre-
serving cells in their native context while eliminating the effect of
stimuli coming from outside the liver. PCLS are an excellent tool
for short-term studies in which cell-cell interactions must be main-
tained [12,13], although the technique has not yet been widely
exploited in the ﬁeld yet. In the current study, the authors exam-
ined the effects of lipopolysaccharide (LPS), a well-known macro-
phage activator, on PCLS from LysM-Cre/PPARc ﬂoxed mice,
demonstrating that these tissue slices were prone to greater levels
of liver injury. In support of a protective role of PPARc, when PCLS
from normal mice were incubated with LPS, injury was attenuated
in the presence of rosiglitazone. Interestingly, in PCLS from Alb-Cre/
PPARc ﬂoxed mice, there was no increased injury following LPS,
suggesting that the increased hepatocyte injury seen in vivo could
indeed be due to inﬁltration of circulating inﬂammatory cells, since
these are not present in the PCLS model.
The study by Morán-Salvador et al. is not perfect, however. Only
one model of liver injury was used, and the LysM-Cre transgene is
also expressed in neutrophils. Thus, the role of PPARc could be
restricted to injury due to CCl4 (although unlikely), and the impor-
tant contribution of neutrophils to the phenotype [14] was not
quantiﬁed. Moreover, it is unclear which subsets of macrophages
express the LysM promoter, even though different subsets could eli-
cit very disparate effects [15]. Also, PCLS were not analyzed from
aP2-Cre ﬂoxed mice, and since the aP2 promoter is active in adipo-
cytes, a role of this cell type in contributing to the liver phenotype
after CCl4 in aP2-Cre/PPARc ﬂoxed mice cannot be excluded.
Do these ﬁndings have any clinical implications? You bet they
do! TZDs have been studied extensively in human liver disease
trials both as agents either to attenuate NASH or to reduce ﬁbro-
sis in patients with chronic HCV, yet the results have not been
impressive in either disease. Perhaps this is because of competing
activities of the drugs in different cell types that undermine their
efﬁcacy, both within liver and among other tissues. In the case of
NASH, it’s fair to say that the effects of rosiglitazone and pioglit-
azone have been modest, at best. In a trial of rosiglitazone from
France, a transient impact on steatosis was evident but there
was no long-term beneﬁt [16]. In the PIVENS trial supported by
the NIDDK NASH Clinical Research Network, pioglitazone
improved both steatosis and lobular inﬂammation but had no916 Journal of Hepatology 201impact on ﬁbrosis [17]. And ﬁnally, in a trial of an experimental
TZD, farglitazar, the drug had no effect on stellate cell activation
or ﬁbrosis in chronic HCV patients [18].
With rising concerns about adverse effects of the current
TZDs, a more targeted approach to inducing PPARc signaling is
necessary, which can only be framed around a clearer picture
of how PPARc activity is regulated in speciﬁc cell types at the
levels of transcription, translation, epigenetics and post-transla-
tional modiﬁcation. As nicely reviewed by Ahmadian and
co-authors [1], newer strategies for selective PPARc agonism
might include the development of more selective ligands that
only affect speciﬁc pathways or tissues, altering post-transla-
tional modiﬁcation of PPARc, using mixed PPAR receptor target-
ing, or regulating speciﬁc lipases to generate lipid ligands for
PPARc within precise cell types. Finally, greater clariﬁcation of
PPARc targets that mediate its effects, for example FGF1 and
FGF21, could lead to efforts to modulate downstream effectors
of PPARc activity rather than the nuclear receptor itself.
In aggregate, the study by Morán-Salvador et al. exploits com-
plementary models to help us understand and embrace the com-
plexity of PPARc signaling, which should lead us towards more
speciﬁc and safer drugs to treat liver disease.Conﬂict of interest
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